Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 17Terminated 9Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 55Other hematologic neoplasm 20Sarcoma 2Plasma cell 1Myeloid 1CNS 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Dexamethasone 48Calcium Dobesilate 20Bortezomib 20Lenalidomide 19Melphalan 16daratumumab 11Cyclophosphamide 11pomalidomide 10elotuzumab 8carfilzomib 8dexamethasone acetate 7pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5selinexor 5fludarabine 5auricularum 5Filgrastim 5liposomal doxorubicin 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Whole-Body Irradiation 3Vorinostat 3Simvastatin 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Rituximab × Plasma cell × Clear all
NCT00004040 2015-08-19

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Hoag Memorial Hospital Presbyterian

Phase 2 Withdrawn
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡